C
Cellarity
Developing medicines through an understanding of cell behaviors
About Cellarity
Cellarity is a groundbreaking startup that is revolutionizing the process of drug creation. The company operates in the pharmaceutical industry, specifically in the area of drug discovery and development. They serve clients in the healthcare sector, including hospitals, clinics, and other medical institutions.
Cellarity's business model is centered around a novel approach to drug discovery. Unlike traditional methods that focus on single molecular targets, Cellarity targets the entire cell, which they believe is a more effective way to treat diseases. This approach is based on a deep understanding of disease biology and leverages advanced technologies like genomics, systems biology, data science, and artificial intelligence (AI).
The company's platform provides insights into cellular dysfunction, revealing new biology that can be used to treat a wide range of diseases. This includes diseases that have been overlooked or are too complex to resolve with traditional methods. With ongoing programs in hematology, immuno-oncology, and metabolism, Cellarity is at the forefront of creating a new generation of medicines.
Cellarity makes money by developing and selling these innovative drugs. Their interdisciplinary team of experts works together to create these new therapies, which are then sold to healthcare providers. The company's unique approach to drug discovery could potentially lead to more effective treatments for a variety of diseases, making it a promising player in the pharmaceutical industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Somerville, United States
- Employees
- 76
- Open positions
- None listed
- Dealroom signal
- 64.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Oct 2022 | $121M | $484M | BlackRock · Kyowa Kirin · The Baupost Group · Pictet | ↗ |
| SERIES BOther financing | Feb 2021 | $123M | $492M | BlackRock · Flagship Pioneering · The Baupost Group · Pictet | — |
Growth signals
Latest recorded traffic for Cellarity is 5.8K monthly website visits, up 48.7% over the last three months. Cellarity's team declined 13.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Flagship Pioneering
BlackRock
The Baupost Group
Pictet
Series B and later2 investors entered at this stage
Kyowa Kirin
Hanwha Impact
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cellarity on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cellarity’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







